Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
CLR457 is a pan-PI3K inhibitor, resulting in apoptosis and growth inhibition in tumor cells overexpressing PI3K (NCI Drug Dictionary).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CLR457||PI3K Inhibitor (Pan) 38||CLR457 is a pan-PI3K inhibitor, resulting in apoptosis and growth inhibition in tumor cells overexpressing PI3K (PMID: 30073466).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||CLR457||Preclinical - Pdx||Actionable||In a preclinical study, CLR457 treatment of a variety of solid tumor patient-derived xenograft models decreased tumor volume and produced a 54% response (PMID: 26479923).||26479923|
|Unknown unknown||Advanced Solid Tumor||not applicable||CLR457||Phase I||Actionable||In a Phase I trial, CLR457 treatment demonstrated limited efficacy, resulting in no confirmed responses, stable disease in 25.8% (8/31) , and non-complete response/non-progressive disease in 6.5% (2/31) of patients with advanced solid tumors with PI3K pathway activation (PMID: 30073466; NCT02189174).||30073466|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02189174||Phase Ib/II||CLR457||Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies||Terminated||USA | CAN||3|